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BMP4 in this process awaits the b cell-
specific inactivation of theBmp4 gene,
a floxed allele of which already exists.
However, as mentioned above, both
Bmp4 and Bmpr1a are expressed in
adult human islets, suggesting that
this pathway is operational in humans
and thusmay be a target for enhancing
insulin secretion in man.
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Nuclear receptors (NRs) are transcription factors whose activities are modulated by the binding of
small lipophilic ligands. The liver X receptors (LXRs) are an important pair ofmammalian NRs that reg-
ulate lipid metabolism upon binding to cholesterol metabolites called oxysterols. A recent report that
LXR activity is also regulated by binding to glucose (Mitro et al., 2007) expands the potential role of
LXR inmetabolic sensing and gene regulation. However, the hydrophilic nature of glucose and its low
affinity for LXR present a challenge to central dogma about the nature of the NR-ligand interaction.Nuclear receptors (NR) are an impor-
tant family of transcription factors
that play a major role in the regulation
of cellular metabolism (Chawla et al.,
2001). First characterized about 20
years ago, the founding members of
the NR family are receptors for steroid
and thyroid hormones that are proven
targets for important pharmaceutical
drugs. The human genome contains
a total of 48 NRs, the majority of which
do not bind to these classical endo-
crine hormones. Over the past two
decades, natural as well as synthetic
ligands have been identified for addi-
tional NRs, including related receptors
for biologically active metabolites of
the fat-soluble vitamins A and D. A re-
markable range of naturally occurringmolecules have been shown to bind
and regulate ‘‘orphan’’ NRs (Table 1).
These discoveries have provoked de-
bate as to the criteria a molecule
should fulfill to be anointed as a physi-
ological ligand. A case in point is the
liver X receptor (LXR), an important
regulator of lipid metabolism whose
activity is controlled by cholesterol
metabolites called oxysterols (see
Zelcer and Tontonoz, 2006 for a gen-
eral review). A recent report fromMitro
et al. (2007) has complicated this sim-
ple picture by suggesting that LXR
may function as a sensor for glucose
in addition to sterol metabolites.
There are two LXR subtypes, one
that is predominantly expressed in
the liver (LXRa, also called RLD-1;Cell MetabolismNR1H3) and one that is widely
expressed (LXRb, also called UR;
NR1H2). LXRa was first described as
an orphan receptor; soon thereafter,
its activity was shown to be regulated
by retinoids, which bind to its hetero-
dimer partner RXR (Willy et al., 1995).
Subsequently, oxysterols were found
to activate LXR (Janowski et al.,
1996), and biochemical and crystallo-
graphic studies prove that they do so
by binding directly to the typical hy-
drophobic pocket in the C-terminal
domain (Williams et al., 2003). The role
of oxysterols as physiological ligands
fits with their lipophilic nature, as well
as with the phenotype of mice lacking
LXRa, whose livers become filled with
cholesterol when fed a Western diet5, March 2007 ª2007 Elsevier Inc. 159
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PreviewsTable 1. Naturally Occurring Ligands for Orphan NRs
Ligand cLogD Affinity Receptor
Phospholipid 7.4–8.6 mM SF1/LRH1, PPAR
Oxysterol 7.3–7.6 mM LXR
Cholesterol sulfate 6.0 mM ROR
Saturated fatty acid 4.8–5.8 <nM HNF4
Unsaturated fatty acid 4.3–4.9 mM PPAR, LXR, RXR
Bile acid 0.5–2.1 mM FXR, VDR
Glucose 2.2 mM LXR
cLogD represents the calculated distribution coefficient between octanol and water at
pH 7.4 corrected for ionization state. The higher the value, the more lipophilic the
ligand. Negative values indicate a preference for water.(Peet et al., 1998). Recently, the role of
oxysterols as physiological ligands
was elegantly confirmed by the knock-
out of oxysterol biosynthesis, which
impairs gene induction by dietary cho-
lesterol in the mouse (Chen et al.,
2007). Unsaturated fatty acids have
also been shown to bind and regulate
LXRa activity in cells. However, in
contrast to the role of oxysterols, the
biological relevance of this observa-
tion has not been established in vivo
(Pawar et al., 2003).
The new finding that LXR may func-
tion as a glucose sensor potentially
places the receptor at a nodal point
between the pathways regulating glu-
cose and lipid metabolism. Both glu-
cose and glucose 6-phosphate (G6P)
appear to fulfill most of the accepted
criteria for NR ligands, including acti-
vation of transcription by LXR in cell-
based assays as well as competition
for ligand binding, direct binding, and
facilitation of coactivator recruitment
in biochemical assays. Furthermore,
Mitro et al. (2007) found that glucose
enhances proteolytic and thermal sta-
bility of LXRa and LXRb, respectively.
This level of proof is similar to that
which originally implicated oxysterols
as LXR ligands and other molecules
as orphan NR ligands (Table 1). So
how should we resolve the dilemma,
when biochemical data indicate multi-
ple diverse candidates as endogenous
ligands for the same receptor?
While awaiting structural studies
that identify the site of glucose binding
to LXR, it is worthwhile to consider
several of Mitro et al. (2007)’s findings
in the context of the general features of160 Cell Metabolism 5, March 2007 ª20NR function. In particular, glucose is
considerably more hydrophilic than
oxysterols or other candidate NR li-
gands (Table 1). The effects of glucose
and G6P appeared to be specific, as
not all hexoses (e.g., galactose) were
found to regulate LXR activity. How-
ever, the ability of G6P to activate in-
tracellular LXR is surprising since this
metabolite does not enter cells effi-
ciently. Moreover, it is remarkable
that L-glucose was nearly as effective
as D-glucose at inducing coactivator
recruitment despite the fact that the
L-enantiomer is absent in mammals,
inactive in most biological reactions,
and unrecognized by well-known cel-
lular mechanisms of glucose sensing
such as glucokinase, the enzyme that
controls glucose-stimulated insulin
secretion from pancreatic b cells
(Matschinsky, 1996). The physiological
relevance of these findings should be
addressed in future work.
Another unusual aspect of glucose
binding to LXR is that the concentra-
tion of glucose required for LXR activa-
tion and binding is in the millimolar
range. This contrasts with the affinities
of oxysterols for LXR and a variety of
candidate ligands for other orphan
NRs, which are in the micromolar
range (Table 1). The classical steroid
and thyroid hormones bind with even
higher affinities for their cognate re-
ceptors. Nevertheless, the biological
relevance of relatively weak ligands is
plausible when their affinity is on the
order of the estimated physiological
concentration. Glucose circulates at
a tightly regulated concentration of
5 mM: a 50% decrease constitutes07 Elsevier Inc.hypoglycemia, and a 50% increase is
diagnostic for diabetes mellitus. Thus,
a key aspect of biological glucose
sensing, as exemplified by glucoki-
nase, is a steep inflection point in the
dose-response curve at 5 mM glu-
cose. The glucose dose-response
curve for LXRa is consistent with this
requirement, but coactivator recruit-
ment to LXRb is maximal at 1 mM
glucose, suggesting that at least one
subtype may be insensitive to the
physiological or even pathophysiolog-
ical changes in glucose concentration.
Mitro et al. (2007) also found that,
when glucose and a potent synthetic
ligand (T0901317) were added to-
gether at saturating concentrations,
both LXRa and LXRb bound coactiva-
tors more avidly. Moreover, when la-
beled versions of the compounds
were present in saturating amounts,
the total binding was greater than
with either alone. These data led the
authors to conclude that glucose
binds to LXRs at more than one site
and may bind simultaneously with
T0901317. However, this simple inter-
pretation does not explain all aspects
of the biochemistry. For example, in
addition to enhancing the total ligand
binding capacity, glucose also dis-
placed both synthetic and oxysterol
ligands from the receptor. To better
understand the underlying mecha-
nism, it would be useful to determine
whether glucose and T0901317 (or
oxysterols) bind to LXR competitively
or noncompetitively by quantifying
the binding at varying concentrations
of both compounds.
Finally, the extent to which LXR con-
tributes to glucose-regulated gene
expression relative to other estab-
lished mechanisms remains to be de-
termined (Towle, 2005). Carbohydrate
response element binding protein
(ChREBP) is a transcription factor
whose activity is regulated by glucose
in a cell-autonomous manner. More-
over, glucose is the main secreta-
gogue for the endocrine hormone
insulin, which regulates gene expres-
sion in many tissues. Thus, the contri-
bution of direct activation of LXR in
the physiological regulation of gene
expression by glucose remains to be
determined. The availability of mice
lacking both LXRa and LXRb should
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Previewsallow this issue to be resolved in the fu-
ture. The findings of Mitro et al. (2007),
if confirmed to be physiologically rele-
vant, may lead to new directions in the
hunt for novel therapeutics that ame-
liorate disorders of glucose and lipid
metabolism. More broadly, these re-
sults should push us to further define
the requirements that distinguish phe-
nomenology from physiology when
evaluating naturally occurring ligands
as potential hormones.
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Holland et al. (2007) provide phar
the development of insulin resist
The modern ‘‘super-size me’’ society
offers an abundance of high-energy
foods that are fueling the fires of
obesity-induced insulin resistance.
Obesity is now recognized as one of
the predisposing factors for the devel-
opment of insulin resistance in skeletal
muscle and liver and a major contribu-
tor to the worldwide escalation in the
incidence of non-insulin-dependent
(type 2) diabetes mellitus. Cushing’s
syndrome is a rare disorder caused
by systemic glucocorticoid excess
that shares many metabolic and mor-
phological similarities with obesity,
including insulin resistance, visceral
obesity, hypertension, and dyslipide-
mia. The overlapping phenotype be-
tween clinical profiles associated withREFERENCES
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lecular mechanism for disease onset.
Given the disease burden and health
costs associated with the rising
prevalence of obesity and common
morbidities such as type 2 diabetes,
hypertension, cardiac failure, and ath-
erosclerosis, efforts to identify and val-
idate mechanisms for the cause and
cure of metabolic disorders are war-
ranted. Emerging evidence suggests
that nutrient excess is associated
with an increase in specific lipid-
derivedmetabolites that inactivate sig-
naling intermediates and cause insulin
resistance. However, the mechanism
by which specific lipid metabolites
cause insulin resistance is incom-
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that ceramide plays a key role in
pletely resolved. In this issue of Cell
Metabolism, Summers and colleagues
(Holland et al., 2007) identify the sphin-
golipid metabolite ceramide as a com-
mon molecular intermediate linking
excess nutrients (i.e., saturated fatty
acids, but not unsaturated fats) and
glucocorticoids to the induction of
insulin resistance.
Several mechanisms have been
proposed to explain how increased
adipose mass affects whole-body in-
sulin sensitivity. One theory is that
adipose-tissue-derived cytokines in-
duce a chronic inflammatory state that
antagonizes insulin signaling and mi-
tochondria function, thereby impair-
ing glucose homeostasis (Hotamisligil,
2006). Another popular theory is based
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